DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eisai - 1 Leqembi - 1 ” - 1 Eric Reiman - 1 Priya Singhal - 1 Biogen - 1 Michael Irizarry - 1 Alzheimer's - 1
Top related locs:
Handout Boston Los Angeles
Top related orgs:
REUTERS - 1 Rights - 1 Banner Alzheimer's Institute - 1 ARIA - 1 Thomson - 1

Search resuls for: "Priya Singhal"


2 mentions found


☆ Injected version of Eisai/Biogen Alzheimer's drug works as well as IV Leqembi
  + stars: | 2023-10-25 | by ( Julie Steenhuysen Deena Beasley | Julie Steenhuysen | Deena Beasley | ) www.reuters.com   time to read: +4 min
The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai/Handout via REUTERS/File Photo Acquire Licensing RightsBOSTON, Oct 25 (Reuters) - An injected version of Eisai (4523.T) and Biogen's (BIIB.O) Alzheimer's drug Leqembi works as well as the current intravenous version at removing toxic brain plaques, according to an analysis presented by Eisai on Wednesday. The Japanese drugmaker's review compared data for 72 patients with early Alzheimer's given Leqembi by subcutaneous injection to prior pivotal trial results from 898 patients who received the drug by infusion. Blood concentration levels of the drug were 11% higher with subcutaneous Leqembi than the IV version. Roll-out of IV Leqembi, which has an annual list price of $26,500, has been slow.
Persons: Eisai, Leqembi, ”, Eric Reiman, Priya Singhal, Biogen, Michael Irizarry, Alzheimer's, Julie Steenhuysen, Deena Beasley, Bill Berkrot, Leslie Adler Organizations: Reuters, REUTERS, Rights, Banner Alzheimer's Institute, ARIA, Thomson Locations: Handout, Boston, Los Angeles
☆ Biogen confident in Alzheimer's drug ahead of rivals' data
  + stars: | 2022-10-25 | by ( Manas Mishra Bhanvi Satija | Manas Mishra | Bhanvi Satija | ) www.reuters.com   time to read: +3 min
Oct 25 (Reuters) - Biogen Inc (BIIB.O) on Tuesday said the Alzheimer's disease drug it is developing with Japan's Eisai Co Ltd (4523.T) would be used by doctors in a competitive market as investors wait for data from rival therapies made by Eli Lilly and Co (LLY.N) and Roche (ROG.S). The drug, lecanemab was shown to slow the progress of the disease by 27% in a trial last month, and additional data is expected next month. "The data needs to be seen from the other anti-amyloid therapies before we decide what is going to be meaningful," said Biogen interim research chief Priya Singhal. Its costs were about halved as the company significantly cut back on commercial infrastructure around the launch of Aduhelm, its previous Alzheimer's drug that has sputtered amid controversy over efficacy and lack of coverage by health insurers. read moreInvestors have been pinning hopes on the Alzheimer's drug as cheaper generics of Biogen's multiple sclerosis treatment Tecfidera have entered the market, hurting sales.
0 next >>
Total: 2